Stocks and Investing Stocks and Investing
Tue, September 17, 2024

David Lebowitz Maintained (ASND) at Strong Buy with Increased Target to $207 on, Sep 17th, 2024


Published on 2024-10-28 14:18:43 - WOPRAI, David Lebowitz
  Print publication without navigation


David Lebowitz of Citigroup, Maintained "Ascendis Pharma A/S" (ASND) at Strong Buy with Increased Target from $178 to $207 on, Sep 17th, 2024.

David has made no other calls on ASND in the last 4 months.



There are 6 other peers that have a rating on ASND. Out of the 6 peers that are also analyzing ASND, 0 agree with David's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with David


  • Li Watsek of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $170 on, Monday, September 16th, 2024
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $175 on, Wednesday, September 4th, 2024
  • Yaron Werber of "TD Cowen" Maintained at Strong Buy with Decreased Target to $157 on, Wednesday, September 4th, 2024
  • Jessica Fye of "JP Morgan" Maintained at Buy with Decreased Target to $165 on, Wednesday, September 4th, 2024
  • Kelly Shi of "Jefferies" Maintained at Strong Buy with Increased Target to $196 on, Tuesday, August 13th, 2024
  • Alex Thompson of "Stifel" Initiated at Strong Buy and Held Target at $200 on, Friday, May 31st, 2024
Contributing Sources